ISRG

Intuitive Surgical Inc

$415.10 -12.20 (-2.86%) At close · Jul 8

Market Cap

$147.01B

354,162,842

Equibles Rating blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Moderate

Market backdrop VIX 16.9 · calm Equity put/call 0.86

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −15%

below

Price vs 50-day avg −3%

below

RSI (14) 49

neutral

MACD trend Positive

52-week position 9%

near low

Momentum

relative strength

Very Weak

1-month return −1%

trailing

6-month return −26%

trailing

YTD return −27%

this year

Relative strength −34%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $426 › 200d $488 — 200d above 50d

Institutional flow Distributing

79 of 2,274 funds reported for Jun 30 · net -585.5K sh shares · +4 new

Insider flow Distributing

Net -$3.1M over 90 days · 100% sells

Short interest Rising

2.20% of float · ▲ +7.4% MoM · 3.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

2,274 holders — mid 3-yr range

Squeeze score 46

elevated · 0–100

Fundamentals

Excellent

Revenue growth +21%

Y/Y

Gross margin 66%

contracting

EPS growth +23%

Y/Y

Valuation P/E 50.4

in line

Buyback $600.0M

remaining

Balance sheet $3.4B

net cash

Quant / Vol

risk profile

Moderate

Volatility 31%

annualized · 1-yr

Max drawdown −33%

past year

ATR 3.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next

Next earnings call

Jul 21, 2026 Est · unconfirmed · in 2 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Apr 22, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Technicals

trend & momentum for long-term holders Sell

2 · 3 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−15% Bearish

Price vs 50-day avg

−3% Neutral

RSI (14)

49 Neutral

MACD trend

Positive Bullish

52-week position

9% Bearish

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $426 › 200d $488 — 200d above 50d

Institutional flow Distributing

79 of 2,274 funds reported for Jun 30 · net -585.5K sh shares · +4 new

Insider flow Distributing

Net -$3.1M over 90 days · 100% sells

Short interest Rising

2.20% of float · ▲ +7.4% MoM · 3.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

2,274 holders — mid 3-yr range

Price context

position in its 52-week range

52-wk low $397 Now $415 · 9% 52-wk high $604

vs 200-day avg -15% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
da Vinci 5 systems placed	232	Q1 2026	—

Da Vinci procedures growth	16%	Q1 2026	—

da Vinci surgical system installed base	11,395	as of March 31, 2026	+2.6%

da Vinci surgical systems placed	431	Q1 2026	—

Ion endoluminal system installed base	1,041	as of March 31, 2026	+4.6%

Ion endoluminal systems placed	52	Q1 2026	—

Ion procedures growth	39%	Q1 2026	—

after-hours procedures growth	31%	Q1 call	—
da Vinci 5 utilization premium over Xi	11%	Q1 call	—
da Vinci procedures	847,000	Q1 call	—

da Vinci systems placed	431	Q1 call	—
Ion procedures	43,000	Q1 call	—

Ion systems placed	52	Q1 call	—
non-GAAP operating margin non-GAAP	39%	Q1 call	—
OUS da Vinci procedures growth	19%	Q1 call	—
OUS procedures as a share of total da Vinci volume	38%	Q1 call	—
OUS total procedures growth	20%	Q1 call	—
SP procedures growth	68%	Q1 call	—
SP stapler usage share	40%	Q1 call	—
SP systems placed	34	Q1 call	—
total procedures growth	17%	Q1 call	—
U.S. cholecystectomy and appendectomy procedures growth	31%	Q1 call	—
U.S. da Vinci bariatrics procedures growth	-10%	Q1 call	—
U.S. da Vinci procedures growth	14%	Q1 call	—
U.S. gynecology procedures growth	10%	Q1 call	—
U.S. non-hysterectomy benign gynecology procedures growth	19%	Q1 call	—
U.S. SP average system utilization growth	22%	Q1 call	—
XiR systems placed	34	Q1 call	—
Da Vinci surgical system installed base growth	12%	as of December 31, 2025	—
Da Vinci systems placed under operating lease arrangements	250	the fourth quarter	—
Da Vinci systems placed under usage-based operating lease arrangements	150	the fourth quarter	—
Ion endoluminal system installed base growth	24%	as of December 31, 2025	—
Average da Vinci system utilization	4%	Q4 2025	—
da Vinci surgical systems placed under operating lease arrangements	872	FY2025	—
da Vinci surgical systems placed under usage-based operating lease arrangements	496	FY2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Medical Instruments & Supplies — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ISRG Intuitive Surgical Inc this stock	$147.01B	-26.7%	+20.5%	50.4	2.2%
MDLN Medline Inc.	$52.94B	-4.0%	+11.5%	—	2.1%
BDX Becton Dickinson & Co	$41.49B	+0.0%	+8.2%	57.2	2.6%
ALC Alcon Inc	$32.46B	-15.5%	—	—	1.8%
RMD Resmed Inc	$29.86B	-14.3%	+13.4%	19.9	8.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

2,273

% held: 80.2%
Reported: 79 of 2,274
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

1,171

View

Short & Settlement

Short Interest Rising

Shares short

7.8M

Days to cover: 3.1d
Change: +535.1K sh

View

Short Volume

Short vol %

36%

As of: Jul 8, 2026

Short Total

View

Fails to Deliver

FTD shares

6.4K

Value: $2.6M
As of: Jun 12, 2026

View

Off-Exchange

Off-exchange %

42.8%

Week of: Jun 15, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$3.1M

Buyers / Sellers: 0 / 4

Buyers Sellers

View

Congressional Trades Buy

Member

Gilbert Cisneros

Amount: $1.0K–$15.0K
Traded: Jan 30, 2026

View

Financials

Revenue (FY)

$10.1B

Net income (FY): $2.9B
EPS diluted: $7.87

View

Buybacks

Authorized

$13.0B

Remaining: $600.0M

Spent Remaining

View

Filings

SEC Filings

Latest

8-K

Filed: May 28, 2026
This year: 9

View

Proposed Sales

Value

$170.6K

Shares: 400
Filed: Jun 10, 2026

View

Earnings & Events

Earnings Calls

Last call

Apr 21, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
ISRG	+4.4%	-0.8%	-26.1%	+4.4%	-26.7%
SPY	-0.2%	+0.8%	+7.4%	-0.2%	+9.3%
vs SPY	+4.6%	-1.7%	-33.6%	+4.6%	-36.0%

Capital returns

Buyback program · as of Mar 31, 2026

Authorized

$13.00B

Spent (derived)

$12.40B

Remaining

$600.00M

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1035267 CUSIP 46120E602 13F (30d) 150 filings 87 filers Visit website Investor relations

ISRG

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns